Phaseline

Companies › Neuboron Bio-SciTech

Neuboron Bio-SciTech: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Oncology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NBB-001 (BPA)
Boron-containing compound for neutron capture therapy
–Phase 2Head and Neck CancerAug 2027
NBB-002 (18F-BPA)
Fluorine-18 labeled boron-containing compound for PET imaging and neutron capture therapy
–Phase 2Head and Neck CancerAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07795034NBB-001 (BPA)Phase 2Head and Neck CancerOncologyAug 2027
NCT07795034NBB-002 (18F-BPA)Phase 2Head and Neck CancerOncologyAug 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Hangzhou Converd Abscint NV/SA Beijing Gene Key Life Technology Beijing Yongtai Ruike Biotechnology Company CNBG-Virogin Biotech (Shanghai)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.